ContraVir's HBV candidate TXL well-tolerated in patients with renal impairmentFeb. 6, 2018 6:57 AM ET|About: ContraVir Pharmaceutic... (CTRV)|By: Douglas W. House, SA News Editor
Resultsfrom a Phase 1 clinical trial evaluating ContraVir Pharmaceuticals' (NASDAQ:CTRV) hepatitis B candidate TXL in eight patients with severe renal impairment and eight patients with normal kidney function showed it to be safe and well-tolerated. In the renal impairment group, blood concentrations of tenofovir (TFV) from a 50 mg dose of TXL were similar to the TFV exposure levels from a 300 mg dose of Gilead Sciences' Viread (tenofovir disoproxil fumarate). The data imply that no dosing strength adjustments for TXL are needed in patients with compromised renal function. Additional results will be submitted for presentation at future scientific conferences. TXL (tenofovir exalidex) is a highly potent prodrug of tenofovir.
Now read: ContraVir (CTRV) Presents At Noble Financial Capital Markets 14th Annual Investor Conference - Slideshow »
ContraVir的HBV候选人TXL对肾功能不全患者耐受良好
Feb. 6，2018 6:57 AM ET |关于：ContraVir制药公司（CTRV）|作者：Douglas W. House，SA新闻编辑
来自评估ContraVir制药公司（纳斯达克：CTRV）乙肝候选人TXL的1期临床试验的结果显示，8例严重肾功能不全患者和8例肾功能正常的患者显示安全且耐受性良好。
在肾损伤组中，来自50mg剂量的TXL的替诺福韦（TFV）的血液浓度与来自300mg剂量的Gilead Sciences的Viread（替诺福韦二吡呋酯富马酸酯）的TFV暴露水平类似。数据表明，肾功能受损患者不需要TXL的剂量强度调整。
其他结果将在未来的科学会议上提交。
TXL（替诺福韦exalidex）是一种非常有效的替诺福韦前药。
现在阅读：ContraVir（CTRV）在诺贝尔金融资本市场第十四届年度投资者大会上发布 - 幻灯片» | 
发表于 2018-2-7 12:15